Carey OConnor Kolaja - May 5, 2021 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
Director
Signature
/s/ Terri McDowell, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
May 5, 2021
Transactions value $
$0
Form type
4
Date filed
5/7/2021, 07:08 PM
Next filing
May 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Award $0 +674 +10.71% $0.00 6.97K May 5, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVNC Stock Option (Right to buy) Award $0 +1.27K $0.00 1.27K May 5, 2021 Common Stock 1.27K $27.91 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 5, 2022, subject to Ms. Kolaja's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
F2 The shares subject to the stock option shall vest on the one year anniversary, May 5, 2022, subject to Ms. Kolaja's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy.